Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Tuesday 19 June, 2018

Oxford BioDynamics

Issue of Equity

RNS Number : 7839R
Oxford BioDynamics PLC
19 June 2018
 

OXFORD BIODYNAMICS PLC

 

Issue of Equity

 

Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 30,000 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options granted under the Company's share option scheme. 

 

The New Shares are expected to be admitted to trading on AIM on 25 June 2018.

 

Following this admission, the Company's share capital and total voting rights comprises 87,513,306 ordinary shares of 1p each and the Company does not hold any shares in treasury. Consequently, 87,513,306 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

-ENDS-

 

 

Oxford BioDynamics Plc.


+44 (0)1865 518910

Christian Hoyer Millar, CEO



Paul Stockdale, CFO






Shore Capital


+44 (0)20 7408 4090

Nominated Adviser and Broker 



Stephane Auton



Edward Mansfield






FTI Consulting  


+44 (0)20 3727 1000

Financial Public Relations Advisor



Julia Phillips



Brett Pollard



Natalie Garland-Collins



 

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOESFMEFAFASEIM

a d v e r t i s e m e n t